International Clinical Trial: A Real-World, Observational Study of Tepotinib Plus EGFR TKIs Versus Other Systemic Therapies in Patients With EGFR-Mutant, MET IHC 2+ Non-Small Cell Lung Cancer in Third-Line and Later Settings

Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118264) titled 'A Real-World, Observational Study of Tepotinib Plus EGFR TKIs Versus Other Systemic Therapies in Patients With EGFR-Mutant, MET IHC 2+ Non-Small Cell Lung Cancer in Third-Line and Later Settings' on Feb. 3.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Ethics Committee of Cancer Hospital of Shandong First Medical University

Condition: Lung Cancer

Intervention: Tepotinib plus EGFR TKI group:N/A

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-02-10

Target Sample Size: Tepotinib plus EGFR TKI group:83;Other systemic therapy group:83;

Countrie...